Palladium Partners’s AstraZeneca AZN Stock Holding History

Palladium Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-200	Closed	-$13K	–	266
2014 Q1	$13K	Buy	+200	New	+$12.9K	﹤0.01%	464
2013 Q4	–	Sell	-250	Closed	-$13K	–	266
2013 Q3	$13K	Hold	250	–	–	﹤0.01%	465
2013 Q2	$12K	Buy	+250	New	+$12.7K	﹤0.01%	482

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Palladium Partners's AZN Position: Q2 2014 in Review

Palladium Partners sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 200 shares — an estimated $13K sold.

Palladium Partners first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $13K in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Palladium Partners reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Palladium Partners sold 200 AstraZeneca shares in Q2 2014, an estimated $13K.
Palladium Partners first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
Palladium Partners's AstraZeneca position peaked at $13K in Q1 2014.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Palladium Partners's 13F filing for Q2 2014, filed 1 Aug 2014.